Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04667156
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04664725
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 179
- Registration Number
- NCT04663282
- Locations
- 🇺🇸
Torrance Clinical Research Institute Inc, Lomita, California, United States
🇦🇺Core Research Group Pty Ltd, Brisbane, Queensland, Australia
🇦🇺The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04649723
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, Shanghai, China
SHR-1701 in Patients With Recurrent/Metastatic Scchn
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT04650633
- Locations
- 🇨🇳
Tumor Hospital of the Chinese Academy of Medical Sciences, Beijing, China
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Conditions
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 687
- Registration Number
- NCT04639180
- Locations
- 🇨🇳
Guangxi Medical University Affiliated Tumor Hospital, Nanjin, Guangzhou, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04631549
- Locations
- 🇨🇳
Guangzhou Eighth People'S Hospital, GuangZhou, Guangdong, China
An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04631575
A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult Subjects
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04627129
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04624217
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China